Main Menu

Akers Biosciences, Inc.

(NASDAQ GS: AKER)

Rigrodsky & Long is investigating Akers Biosciences, Inc. (“Akers”) regarding possible breaches of fiduciary duties and other violations of law related to Akers' agreement to merge with MYMD Pharmaceuticals, Inc. ("MYMD").  Under the terms of the agreement, Akers will issue a number of shares of Akers' common stock to shareholders of MYMD. Upon completion of the merger, Akers' shareholders will own approximately 20% of the combined company and MYMD's shareholders will own approximately 80% of the combined company. 

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 11/26/2020


* Indicates a required field.

Back to Page